Arvind Kush

CIK: 0001986806

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IKT

Inhibikase Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

IKT
Inhibikase Therapeutics, Inc.
Jun 30, 2025
Award(A)
Stock Option (Right to Buy)
Direct
108.2K shares-
IKT
Inhibikase Therapeutics, Inc.
Feb 14, 2025
Award(A)
Stock Option (Right to Buy)
Direct
56.6K shares-
IKT
Inhibikase Therapeutics, Inc.
Feb 14, 2025
Award(A)
Stock Option (Right to Buy)
Direct
116.6K shares-
IKT
Inhibikase Therapeutics, Inc.
Oct 21, 2024
Purchase(P)
Direct
145K shares at avg. $1.37$199K
IKT
Inhibikase Therapeutics, Inc.
Oct 21, 2024
Award(A)
Stock Option (right to buy)
Direct
60K shares-

		Type	Shares	Price		Ownership
Jun 30, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	108,176	-	-	Direct
Feb 14, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	56,600	-	-	Direct
Feb 14, 2025	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	116,585	-	-	Direct
Oct 21, 2024	IKT Inhibikase Therapeutics, Inc.	Purchase(P)	145,000	$1.37	$198,650	Direct
Oct 21, 2024	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (right to buy)	60,000	-	-	Direct

1-5 of 5 transactions

About Kush Arvind

Kush Arvind (SEC CIK 0001986806) files insider reports with the SEC as Director of Inhibikase Therapeutics, Inc. (IKT).

Signal8 holds 4 ownership filings by Kush Arvind (1 Form 3, 3 Form 4), filed between Oct 23, 2024 and Jul 2, 2025. Those filings report 5 transactions, from Oct 21, 2024 to Jun 30, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Kush Arvind's filings is in ATLANTA, GA.

Recent filings by Kush Arvind

Jun 30, 2025: Grant or award of IKT derivative securities (Form 4, code A).
Feb 14, 2025: Grants or awards of IKT derivative securities (2 lines, Form 4, code A).
Oct 21, 2024: Open-market purchase of IKT shares (Form 4, code P).
Oct 21, 2024: Grant or award of IKT derivative securities (Form 4, code A).

Other insiders filing for Inhibikase Therapeutics, Inc. (IKT)

Wasserman Scott M., Director
RA CAPITAL MANAGEMENT, L.P., 10% Owner
Aurentz Vincent, Director
Cabell Christopher, President & Head of R&D
Munshi Amit, Director
Iwicki Mark T, Chief Executive Officer

How to read Form 4 transaction codes